{
    "info": {
        "nct_id": "NCT05222984",
        "official_title": "A Phase Ib Open Label Study of Navitoclax in Combination With Venetoclax + Decitabine in Relapsed/Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax",
        "inclusion_criteria": "* Documented informed consent of the participant and/or legally authorized representative\n* For participants under the age of 18 years, documentation of adolescent assent by the participant and consent of both parents or guardian\n* Adults aged >= 18 years\n* Adolescent patients aged >= 16 years and < 18 years weighing at least 45 kg who have no other standard-of-care option for treatment\n* Eastern Cooperative Oncology Group (ECOG) =< 2\n* Patients with histologically confirmed AML, according to World Health Organization (WHO) criteria, with refractory/relapsed (R/R) disease following a venetoclax-containing regimen who are ineligible for therapies known to be effective for treatment of their AML.\n\n  * Patients with extramedullary disease may be included if they also have marrow involvement\n  * Patients with acute promyelocytic leukemia (APL) will not be eligible\n* Fully recovered from the acute toxic effects (except alopecia) to =< grade 1 of prior anti-cancer therapy\n* Ability to swallow pills\n* Absolute neutrophil count (ANC) >= 750/mm^3 (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)\n\n  * NOTE: Growth factor is not permitted within 14 days of ANC assessment unless cytopenia is secondary to disease involvement\n* White blood cell (WBC) =< 25 x 10^9/L prior to initiation of study therapy. Cytoreduction with hydroxyurea prior to treatment and/or during cycle 1 may be required (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)\n* Platelets >= 75,000/mm^3\n\n  * NOTE: Platelet transfusions are not permitted within 14 days of platelet assessment unless cytopenia is secondary to disease involvement\n* Total bilirubin =< 1.5 X upper limit of normal (ULN) (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)\n* Aspartate aminotransferase (AST) =< 3.0 x ULN (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)\n* Alanine aminotransferase (ALT) =< 3.0 x ULN (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)\n* Creatinine clearance of >= 45 ml/min per 24-hour urine test or the Cockcroft-Gault formula (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)\n* If in the absence of anticoagulants: International normalized ratio (INR) OR prothrombin (PT) =< 1.5 x ULN (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)\n* If in the absence of anticoagulants: Activated partial thromboplastin time (aPTT) =< 1.5 x ULN (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)\n* Left ventricular ejection fraction (LVEF) >= 50%\n\n  * Note: To be performed within 28 days prior to day 1 of protocol therapy\n* Corrected QT interval (QTc) =< 480 ms\n\n  * Note: To be performed within 28 days prior to day 1 of protocol therapy\n* Seronegative for human immunodeficiency virus (HIV) antigen (Ag)/antibody (Ab) combo, hepatitis C virus (HCV), active hepatitis B virus (HBV) (surface antigen negative), and syphilis (RPR) (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)\n\n  * If positive, Hepatitis C RNA quantitation must be performed\n* Meets other institutional and federal requirements for infectious disease titer requirements\n\n  * Note Infectious disease testing to be performed within 28 days prior to day 1 of protocol therapy\n* Women of child-bearing potential (WOCBP): negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)\n* Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 3 months (males) and 6 months (females) after the last dose of protocol therapy\n\n  * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)\nHealthy volunteers allowed\nMust have minimum age of 16 Years",
        "exclusion_criteria": "* Hematopoietic stem cell transplant within 100 days prior to day 1 of protocol therapy\n* Chemotherapy, radiation therapy, biological therapy, or immunotherapy within 14 days or 5 half-lives, whichever is shorter, prior to day 1 of protocol therapy with the following exceptions:\n\n  * Subjects will be allowed to have been on venetoclax at screening and remain on it through treatment start.\n  * Hydroxyurea is allowed prior to treatment and through cycle 1 for control of rapidly progressing leukemia\n* Strong or moderate CYP3A4 inducers within 14 days prior to day 1 of protocol therapy\n* Grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or star fruit consumed within 3 days prior to the first dose of study drug\n* Immunosuppressants (steroids =< 10 mg/day of oral prednisone or equivalent is allowed) within the last 28 days\n* Hematopoietic growth factors in the last 14 days\n* Must not have received or planning to receive live vaccine while being on study or 4 weeks before and after completion of treatment\n* Herbal medications known to affect platelet function within 14 days of therapy initiation\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent\n* Active graft-versus-host-disease (GVHD)\n* Active central nervous system (CNS) disease\n* No measurable disease in the bone marrow\n* Active diarrhea\n* Gastrointestinal disorder that interferes with oral drug absorption such as malabsorption syndrome\n* Clinically significant cardiac morbidities (class III/IV cardiovascular disability according to the New York Heart Association classification, arrhythmia not stable on medical management, acute cardiovascular ischemic event within 6 months of enrollment, etc.)\n* Clinically significant uncontrolled illness\n* Active infection requiring antibiotics\n* Active/uncontrolled HIV infection, acquired immunodeficiency syndrome (AIDS), or currently taking contraindicated medications for HIV control\n* Diagnosis of Gilbert's disease\n* Any other active malignancy at time of enrollment. Exceptions include basal/squamous cell carcinoma, in situ adequately treated breast and uterine cancer\n* Females only: Pregnant or breastfeeding\n* Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures\n* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Platelets >= 75,000/mm^3",
            "criterions": [
                {
                    "exact_snippets": "Platelets >= 75,000/mm^3",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75000,
                                "unit": "mm^3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)",
            "criterions": [
                {
                    "exact_snippets": "not being surgically sterilized (men and women)",
                    "criterion": "surgical sterilization status",
                    "requirements": [
                        {
                            "requirement_type": "sterilization status",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "have not been free from menses for > 1 year (women only)",
                    "criterion": "menstrual status (women only)",
                    "requirements": [
                        {
                            "requirement_type": "time since last menses",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Seronegative for human immunodeficiency virus (HIV) antigen (Ag)/antibody (Ab) combo, hepatitis C virus (HCV), active hepatitis B virus (HBV) (surface antigen negative), and syphilis (RPR) (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)",
            "criterions": [
                {
                    "exact_snippets": "Seronegative for human immunodeficiency virus (HIV) antigen (Ag)/antibody (Ab) combo",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "serostatus",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "Seronegative for ... hepatitis C virus (HCV)",
                    "criterion": "hepatitis C virus infection",
                    "requirements": [
                        {
                            "requirement_type": "serostatus",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "Seronegative for ... active hepatitis B virus (HBV) (surface antigen negative)",
                    "criterion": "active hepatitis B virus infection",
                    "requirements": [
                        {
                            "requirement_type": "surface antigen status",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "Seronegative for ... syphilis (RPR)",
                    "criterion": "syphilis infection",
                    "requirements": [
                        {
                            "requirement_type": "serostatus (RPR)",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "performed within 14 days prior to day 1 of protocol therapy",
                    "criterion": "infectious disease serology testing timing",
                    "requirements": [
                        {
                            "requirement_type": "time before protocol therapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin =< 1.5 X upper limit of normal (ULN) (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin =< 1.5 X upper limit of normal (ULN)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Note Infectious disease testing to be performed within 28 days prior to day 1 of protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "Infectious disease testing to be performed within 28 days prior to day 1 of protocol therapy",
                    "criterion": "infectious disease testing",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 28 days prior to day 1 of protocol therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with acute promyelocytic leukemia (APL) will not be eligible",
            "criterions": [
                {
                    "exact_snippets": "Patients with acute promyelocytic leukemia (APL) will not be eligible",
                    "criterion": "acute promyelocytic leukemia (APL)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 16 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 16 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 16,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with histologically confirmed AML, according to World Health Organization (WHO) criteria, with refractory/relapsed (R/R) disease following a venetoclax-containing regimen who are ineligible for therapies known to be effective for treatment of their AML.",
            "criterions": [
                {
                    "exact_snippets": "histologically confirmed AML",
                    "criterion": "acute myeloid leukemia (AML) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "histological"
                        }
                    ]
                },
                {
                    "exact_snippets": "according to World Health Organization (WHO) criteria",
                    "criterion": "AML diagnosis criteria",
                    "requirements": [
                        {
                            "requirement_type": "diagnostic criteria",
                            "expected_value": "WHO"
                        }
                    ]
                },
                {
                    "exact_snippets": "refractory/relapsed (R/R) disease following a venetoclax-containing regimen",
                    "criterion": "disease status after venetoclax-containing regimen",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "refractory",
                                "relapsed"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "ineligible for therapies known to be effective for treatment of their AML",
                    "criterion": "eligibility for effective AML therapies",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ability to swallow pills",
            "criterions": [
                {
                    "exact_snippets": "Ability to swallow pills",
                    "criterion": "ability to swallow pills",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* White blood cell (WBC) =< 25 x 10^9/L prior to initiation of study therapy. Cytoreduction with hydroxyurea prior to treatment and/or during cycle 1 may be required (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)",
            "criterions": [
                {
                    "exact_snippets": "White blood cell (WBC) =< 25 x 10^9/L prior to initiation of study therapy",
                    "criterion": "white blood cell count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 25,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Cytoreduction with hydroxyurea prior to treatment and/or during cycle 1 may be required",
                    "criterion": "cytoreduction with hydroxyurea",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": "may be required prior to treatment and/or during cycle 1"
                        }
                    ]
                },
                {
                    "exact_snippets": "performed within 14 days prior to day 1 of protocol therapy unless otherwise stated",
                    "criterion": "timing of cytoreduction with hydroxyurea",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 14 days prior to day 1 of protocol therapy unless otherwise stated"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) =< 2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) =< 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For participants under the age of 18 years, documentation of adolescent assent by the participant and consent of both parents or guardian",
            "criterions": [
                {
                    "exact_snippets": "participants under the age of 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": "<",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "documentation of adolescent assent by the participant",
                    "criterion": "adolescent assent documentation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "consent of both parents or guardian",
                    "criterion": "parental or guardian consent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adults aged >= 18 years",
            "criterions": [
                {
                    "exact_snippets": "Adults aged >= 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Left ventricular ejection fraction (LVEF) >= 50%",
            "criterions": [
                {
                    "exact_snippets": "Left ventricular ejection fraction (LVEF) >= 50%",
                    "criterion": "left ventricular ejection fraction (LVEF)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with extramedullary disease may be included if they also have marrow involvement",
            "criterions": [
                {
                    "exact_snippets": "extramedullary disease",
                    "criterion": "extramedullary disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "if they also have marrow involvement",
                    "criterion": "marrow involvement",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC) >= 750/mm^3 (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) >= 750/mm^3",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 750,
                                "unit": "mm^3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Fully recovered from the acute toxic effects (except alopecia) to =< grade 1 of prior anti-cancer therapy",
            "criterions": [
                {
                    "exact_snippets": "Fully recovered from the acute toxic effects (except alopecia) to =< grade 1 of prior anti-cancer therapy",
                    "criterion": "acute toxic effects of prior anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "grade"
                            }
                        },
                        {
                            "requirement_type": "recovery_status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "(except alopecia)",
                    "criterion": "alopecia",
                    "requirements": [
                        {
                            "requirement_type": "exclusion_from_recovery_requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Corrected QT interval (QTc) =< 480 ms",
            "criterions": [
                {
                    "exact_snippets": "Corrected QT interval (QTc) =< 480 ms",
                    "criterion": "corrected QT interval (QTc)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 480,
                                "unit": "ms"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NOTE: Platelet transfusions are not permitted within 14 days of platelet assessment unless cytopenia is secondary to disease involvement",
            "criterions": [
                {
                    "exact_snippets": "Platelet transfusions are not permitted within 14 days of platelet assessment",
                    "criterion": "platelet transfusions",
                    "requirements": [
                        {
                            "requirement_type": "time since last transfusion",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless cytopenia is secondary to disease involvement",
                    "criterion": "cytopenia secondary to disease involvement",
                    "requirements": [
                        {
                            "requirement_type": "cause",
                            "expected_value": "secondary to disease involvement"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women of child-bearing potential (WOCBP): negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)",
            "criterions": [
                {
                    "exact_snippets": "Women of child-bearing potential (WOCBP)",
                    "criterion": "sex and reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "child-bearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "negative urine or serum pregnancy test",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnancy test result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "serum pregnancy test will be required (performed within 14 days prior to day 1 of protocol therapy",
                    "criterion": "serum pregnancy test timing",
                    "requirements": [
                        {
                            "requirement_type": "test timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to day 1 of protocol therapy"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aspartate aminotransferase (AST) =< 3.0 x ULN (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) =< 3.0 x ULN",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3.0,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Alanine aminotransferase (ALT) =< 3.0 x ULN (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)",
            "criterions": [
                {
                    "exact_snippets": "Alanine aminotransferase (ALT) =< 3.0 x ULN",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3.0,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adolescent patients aged >= 16 years and < 18 years weighing at least 45 kg who have no other standard-of-care option for treatment",
            "criterions": [
                {
                    "exact_snippets": "Adolescent patients aged >= 16 years and < 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 16,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<",
                                        "value": 18,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "weighing at least 45 kg",
                    "criterion": "weight",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 45,
                                "unit": "kg"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "who have no other standard-of-care option for treatment",
                    "criterion": "standard-of-care treatment options",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Creatinine clearance of >= 45 ml/min per 24-hour urine test or the Cockcroft-Gault formula (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)",
            "criterions": [
                {
                    "exact_snippets": "Creatinine clearance of >= 45 ml/min per 24-hour urine test or the Cockcroft-Gault formula",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 45,
                                "unit": "ml/min"
                            }
                        },
                        {
                            "requirement_type": "measurement_method",
                            "expected_value": [
                                "24-hour urine test",
                                "Cockcroft-Gault formula"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "performed within 14 days prior to day 1 of protocol therapy",
                    "criterion": "creatinine clearance measurement timing",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 14 days prior to day 1 of protocol therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 3 months (males) and 6 months (females) after the last dose of protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 3 months (males) and 6 months (females) after the last dose of protocol therapy",
                    "criterion": "contraception or abstinence during and after study",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use effective birth control or abstain from heterosexual activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration (males)",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "duration (females)",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Meets other institutional and federal requirements for infectious disease titer requirements",
            "criterions": [
                {
                    "exact_snippets": "Meets other institutional and federal requirements for infectious disease titer requirements",
                    "criterion": "infectious disease titer",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": "Meets institutional and federal requirements"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If positive, Hepatitis C RNA quantitation must be performed",
            "criterions": [
                {
                    "exact_snippets": "If positive, Hepatitis C RNA quantitation must be performed",
                    "criterion": "Hepatitis C RNA quantitation",
                    "requirements": [
                        {
                            "requirement_type": "requirement for testing",
                            "expected_value": "if positive for Hepatitis C, RNA quantitation must be performed"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If in the absence of anticoagulants: International normalized ratio (INR) OR prothrombin (PT) =< 1.5 x ULN (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)",
            "criterions": [
                {
                    "exact_snippets": "If in the absence of anticoagulants: International normalized ratio (INR) OR prothrombin (PT) =< 1.5 x ULN",
                    "criterion": "anticoagulant use",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "International normalized ratio (INR) ... =< 1.5 x ULN",
                    "criterion": "International normalized ratio (INR)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "prothrombin (PT) =< 1.5 x ULN",
                    "criterion": "prothrombin time (PT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "performed within 14 days prior to day 1 of protocol therapy",
                    "criterion": "laboratory test timing",
                    "requirements": [
                        {
                            "requirement_type": "time window",
                            "expected_value": "within 14 days prior to day 1 of protocol therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Documented informed consent of the participant and/or legally authorized representative",
            "criterions": [
                {
                    "exact_snippets": "Documented informed consent of the participant",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "source",
                            "expected_value": "participant"
                        }
                    ]
                },
                {
                    "exact_snippets": "Documented informed consent ... legally authorized representative",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "source",
                            "expected_value": "legally authorized representative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NOTE: Growth factor is not permitted within 14 days of ANC assessment unless cytopenia is secondary to disease involvement",
            "criterions": [
                {
                    "exact_snippets": "Growth factor is not permitted within 14 days of ANC assessment",
                    "criterion": "growth factor administration",
                    "requirements": [
                        {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless cytopenia is secondary to disease involvement",
                    "criterion": "cytopenia etiology",
                    "requirements": [
                        {
                            "requirement_type": "cause",
                            "expected_value": "secondary to disease involvement"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If in the absence of anticoagulants: Activated partial thromboplastin time (aPTT) =< 1.5 x ULN (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)",
            "criterions": [
                {
                    "exact_snippets": "If in the absence of anticoagulants: Activated partial thromboplastin time (aPTT) =< 1.5 x ULN",
                    "criterion": "activated partial thromboplastin time (aPTT)",
                    "requirements": [
                        {
                            "requirement_type": "anticoagulant use",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Hematopoietic growth factors in the last 14 days",
            "criterions": [
                {
                    "exact_snippets": "Hematopoietic growth factors in the last 14 days",
                    "criterion": "hematopoietic growth factor use",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Strong or moderate CYP3A4 inducers within 14 days prior to day 1 of protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "Strong or moderate CYP3A4 inducers within 14 days prior to day 1 of protocol therapy",
                    "criterion": "CYP3A4 inducer use",
                    "requirements": [
                        {
                            "requirement_type": "strength",
                            "expected_value": [
                                "strong",
                                "moderate"
                            ]
                        },
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to day 1 of protocol therapy"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diagnosis of Gilbert's disease",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of Gilbert's disease",
                    "criterion": "Gilbert's disease",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects will be allowed to have been on venetoclax at screening and remain on it through treatment start.",
            "criterions": [
                {
                    "exact_snippets": "Subjects will be allowed to have been on venetoclax at screening and remain on it through treatment start.",
                    "criterion": "venetoclax use",
                    "requirements": [
                        {
                            "requirement_type": "allowed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active graft-versus-host-disease (GVHD)",
            "criterions": [
                {
                    "exact_snippets": "Active graft-versus-host-disease (GVHD)",
                    "criterion": "graft-versus-host-disease (GVHD)",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active diarrhea",
            "criterions": [
                {
                    "exact_snippets": "Active diarrhea",
                    "criterion": "diarrhea",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clinically significant uncontrolled illness",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant uncontrolled illness",
                    "criterion": "clinically significant uncontrolled illness",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hydroxyurea is allowed prior to treatment and through cycle 1 for control of rapidly progressing leukemia",
            "criterions": [
                {
                    "exact_snippets": "Hydroxyurea is allowed prior to treatment and through cycle 1 for control of rapidly progressing leukemia",
                    "criterion": "hydroxyurea use",
                    "requirements": [
                        {
                            "requirement_type": "permitted timing",
                            "expected_value": [
                                "prior to treatment",
                                "through cycle 1"
                            ]
                        },
                        {
                            "requirement_type": "purpose",
                            "expected_value": "control of rapidly progressing leukemia"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Herbal medications known to affect platelet function within 14 days of therapy initiation",
            "criterions": [
                {
                    "exact_snippets": "Herbal medications known to affect platelet function within 14 days of therapy initiation",
                    "criterion": "herbal medication use affecting platelet function",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "effect on platelet function",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Chemotherapy, radiation therapy, biological therapy, or immunotherapy within 14 days or 5 half-lives, whichever is shorter, prior to day 1 of protocol therapy with the following exceptions:",
            "criterions": [
                {
                    "exact_snippets": "Chemotherapy, radiation therapy, biological therapy, or immunotherapy within 14 days or 5 half-lives, whichever is shorter, prior to day 1 of protocol therapy",
                    "criterion": "prior anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "chemotherapy",
                                "radiation therapy",
                                "biological therapy",
                                "immunotherapy"
                            ]
                        },
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 14,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hematopoietic stem cell transplant within 100 days prior to day 1 of protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "Hematopoietic stem cell transplant within 100 days prior to day 1 of protocol therapy",
                    "criterion": "hematopoietic stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">",
                                "value": 100,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Females only: Pregnant or breastfeeding",
            "criterions": [
                {
                    "exact_snippets": "Females only",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                },
                {
                    "exact_snippets": "Pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clinically significant cardiac morbidities (class III/IV cardiovascular disability according to the New York Heart Association classification, arrhythmia not stable on medical management, acute cardiovascular ischemic event within 6 months of enrollment, etc.)",
            "criterions": [
                {
                    "exact_snippets": "class III/IV cardiovascular disability according to the New York Heart Association classification",
                    "criterion": "cardiovascular disability (NYHA classification)",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "class III",
                                "class IV"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "arrhythmia not stable on medical management",
                    "criterion": "arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "stability on medical management",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "acute cardiovascular ischemic event within 6 months of enrollment",
                    "criterion": "acute cardiovascular ischemic event",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Immunosuppressants (steroids =< 10 mg/day of oral prednisone or equivalent is allowed) within the last 28 days",
            "criterions": [
                {
                    "exact_snippets": "Immunosuppressants (steroids =< 10 mg/day of oral prednisone or equivalent is allowed) within the last 28 days",
                    "criterion": "immunosuppressant use",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "allowed exception",
                            "expected_value": "steroids <= 10 mg/day of oral prednisone or equivalent"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or star fruit consumed within 3 days prior to the first dose of study drug",
            "criterions": [
                {
                    "exact_snippets": "Grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or star fruit consumed within 3 days prior to the first dose of study drug",
                    "criterion": "consumption of grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges), or star fruit",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "days prior to the first dose of study drug"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active infection requiring antibiotics",
            "criterions": [
                {
                    "exact_snippets": "Active infection requiring antibiotics",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "requiring antibiotics"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures",
            "criterions": [
                {
                    "exact_snippets": "Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures",
                    "criterion": "other condition contraindicating participation due to safety concerns",
                    "requirements": [
                        {
                            "requirement_type": "investigator judgment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "safety concern with clinical study procedures",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Gastrointestinal disorder that interferes with oral drug absorption such as malabsorption syndrome",
            "criterions": [
                {
                    "exact_snippets": "Gastrointestinal disorder that interferes with oral drug absorption",
                    "criterion": "gastrointestinal disorder",
                    "requirements": [
                        {
                            "requirement_type": "interference with oral drug absorption",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "malabsorption syndrome",
                    "criterion": "malabsorption syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Must not have received or planning to receive live vaccine while being on study or 4 weeks before and after completion of treatment",
            "criterions": [
                {
                    "exact_snippets": "Must not have received ... live vaccine while being on study or 4 weeks before and after completion of treatment",
                    "criterion": "live vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 4,
                                        "unit": "weeks before completion of treatment"
                                    },
                                    {
                                        "operator": ">",
                                        "value": 4,
                                        "unit": "weeks after completion of treatment"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent",
            "criterions": [
                {
                    "exact_snippets": "History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent",
                    "criterion": "allergic reactions to compounds of similar chemical or biologic composition to study agent",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any other active malignancy at time of enrollment. Exceptions include basal/squamous cell carcinoma, in situ adequately treated breast and uterine cancer",
            "criterions": [
                {
                    "exact_snippets": "Any other active malignancy at time of enrollment",
                    "criterion": "active malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Exceptions include basal/squamous cell carcinoma, in situ adequately treated breast and uterine cancer",
                    "criterion": "basal cell carcinoma, squamous cell carcinoma, in situ adequately treated breast cancer, in situ adequately treated uterine cancer",
                    "requirements": [
                        {
                            "requirement_type": "exception",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active/uncontrolled HIV infection, acquired immunodeficiency syndrome (AIDS), or currently taking contraindicated medications for HIV control",
            "criterions": [
                {
                    "exact_snippets": "Active/uncontrolled HIV infection",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active or uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "acquired immunodeficiency syndrome (AIDS)",
                    "criterion": "acquired immunodeficiency syndrome (AIDS)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "currently taking contraindicated medications for HIV control",
                    "criterion": "medications for HIV control",
                    "requirements": [
                        {
                            "requirement_type": "contraindicated medication use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",
            "criterions": [
                {
                    "exact_snippets": "may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",
                    "criterion": "ability to comply with study procedures",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in the opinion of the investigator",
                    "criterion": "investigator's judgment of participant suitability",
                    "requirements": [
                        {
                            "requirement_type": "investigator judgment",
                            "expected_value": "suitable for study procedures"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active central nervous system (CNS) disease",
            "criterions": [
                {
                    "exact_snippets": "Active central nervous system (CNS) disease",
                    "criterion": "central nervous system (CNS) disease",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No measurable disease in the bone marrow",
            "criterions": [
                {
                    "exact_snippets": "No measurable disease in the bone marrow",
                    "criterion": "measurable disease in the bone marrow",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* Note: To be performed within 28 days prior to day 1 of protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "to be performed within 28 days prior to day 1 of protocol therapy",
                    "criterion": "required assessments or procedures",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to day 1 of protocol therapy"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Note: To be performed within 28 days prior to day 1 of protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "to be performed within 28 days prior to day 1 of protocol therapy",
                    "criterion": "required assessments or procedures",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to day 1 of protocol therapy"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}